Shanghai Pharmaceuticals Holding Co. Ltd. possessing the leading positions in both the markets of pharmaceutical products and distribution, announced its pro tem results for the H1, 2015 on Aug 27th, 2015.
Various factors such as the slowdown in the macro-economic condition, rise in drug prices and public hospitals’ expenses and many others have led to a sluggish growth in the revenue and profit in the Chinese pharmaceutical sector in the first half of 2015.
Shanghai Pharmaceuticals has enhanced its managing capabilities and triggered the core competition, stimulating the development of its business. The company is making good progress and attained a revenue of more than RMB100 billion in the first half of 2015.
In the H1 2015, the operating revenue of the pharma company stood at RMB50.950 billion, reporting an increase by 15.76% on a year-on-year basis. The net profit to be distributed among the shareholders of the firm was RMB1.534 billion, showing a growth of 16.39% on a year-on-year basis.
The operating net revenue after deducting administrational and sales costs was 4.09%. The basic EPS valued at RMB0.5705 and basic EPS after deducting nonrecurring returns and losses amounted to RMB0.5413, showing a rise of 21.59% on a year-on-year basis.
The net cash flows of the firm from the operating activities totaled to RMB482 million, which was up by 77.96% on a year-on-year basis. As of June 30th, 2015, the equity shares of the owners of the Company was RMB31.967 billion, whereas the equity shares of them after the deduction of the minority interest came around RMB28.491 billion. The total assets was amounted to RMB69.886 billion.